Journal of Pharmaceutical Research International · 2021 · 16 citations · 11 references
MedicineInfectious DiseasesPharmacotherapyClinical EpidemiologyCritical Care MedicineCritical Care PharmacotherapyAcute Respiratory Distress SyndromeAcute Respiratory FailureCritical Care PulmonologyIntensive Care MedicineRespiratory DiseaseRespiratory Failure ManagementCovid-19-associated Acute Respiratory Distress SyndromeDisease Prognostic BiomarkersIntensive Care UsePrognostic BiomarkersRespiratory Failure PrognosisRespiratory Failure PrognosticationSevere Acute Respiratory SyndromeTertiary Care Organization
Since the first detection of a cluster of COVID-19 patients in China in late 2019, it becomes a global concern due to its transmissibility and ability to progress patients in severe respiratory failure and acute respiratory distress syndrome, which need intensive care unit support for a long time. We observed the repurposing use of remdesivir and favipiravir whether considered as a therapeutic option or not through survival rate and changes in biomarker during 10-day treatment stay in ICU. The retrospective observational study in a tertiary care hospital dedicated to COVID-19 at Dhaka, Bangladesh was done at the peak of COVID-19 pandemic in Bangladesh. The mortality rate, length of ICU stays and eight prognostic biomarkers of patients treated with remdesivir and favipiravir was observed as one of the first ever reported experience in Bangladesh. Among the critically ill patients in ICU, 26 (44.8%) died and 32 (55.2%) were cured during the study period and highest mean duration of stay in ICU was observed (14.33 days and 18.13 days) in FPV-treated patients. Mean of means for all biomarkers CRP (26.0) and d-Dimer (2.64) was recorded higher in favipiravir treated patients in death cases, but NLR, d-NLR, platelet, PLR was much higher in remdesivir treated patient of both death and improved cases. Though overall outcome variables between death and improved cases were not statistically significant (p<0.39) The severity of disease progression in critically ill COVID-19 patients in ICU depends on comorbidities and hyper-responsive inflammatory or immunological biomarkers to predict. Though the emergency use authorization and repurposing use of different antivirals are still on trial, but remdesivir and favipiravir revealed not much hope in improving prognostic biomarkers, survival rate and disease progression at the peak of pandemic in Bangladesh.
11
Remdesivir for the Treatment of Covid-19 — Final Report
John H. Beigel, Kay M Tomashek, Lori E. Dodd et al. · New England Journal of Medicine · 2020 · 7.7K citations · Full text
Stephen A. Lauer, Kyra H. Grantz, Qifang Bi et al. · Annals of Internal Medicine · 2020 · 6.6K citations · Full text
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17